menu
    • menu
    [{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"EDISON PHARMACEUTICALS INC","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Neurology","graph2":"Phase II","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EDISON PHARMACEUTICALS INC \/ EDISON PHARMACEUTICALS INC","highestDevelopmentStatusID":"8","companyTruncated":"EDISON PHARMACEUTICALS INC \/ EDISON PHARMACEUTICALS INC"},{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EDISON PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EDISON PHARMACEUTICALS INC \/ Undisclosed"},{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Neurology","graph2":"Phase II","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"EDISON PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EDISON PHARMACEUTICALS INC \/ Undisclosed"},{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EDISON PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EDISON PHARMACEUTICALS INC \/ Undisclosed"},{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EDISON PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EDISON PHARMACEUTICALS INC \/ Undisclosed"},{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EDISON PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"EDISON PHARMACEUTICALS INC \/ Undisclosed"},{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"PTC-589","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EDISON PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EDISON PHARMACEUTICALS INC \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by EDISON PHARMACEUTICALS INC

    Menu

    EDISON PHARMACEUTICALS INC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTC-589

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease

                            Details : PTC-589 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 04, 2015

                            Lead Product(s) : PTC-589

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

                            Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Optic Atrophy, Hereditary, Leber.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 25, 2014

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Protective Effects of EPI-743 on Noise-Induced Hearing Loss

                            Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hearing Loss, Noise-Induced.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 07, 2014

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder

                            Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autism Spectrum Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 27, 2014

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of EPI-743 in Children With Pearson Syndrome

                            Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of VLCAD Deficiency.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2014

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : University of South Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease

                            Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 15, 2013

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : University of South Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            EDISON PHARMACEUTICALS INC

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

                            Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rett Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 02, 2013

                            Lead Product(s) : Vatiquinone

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth